How well tolerated are lipid-lowering drugs?

Drugs and Aging

Volumn 18, Issue 9, 2001, Pages 665-683

  Tomlinson, B ^a   Chan, P ^b   Lan, W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; COLESTYRAMINE; DIGOXIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; NICOTINIC ACID; STATINE DERIVATIVE; WARFARIN;

BEHAVIOR DISORDER; BRAIN HEMORRHAGE; CARCINOGENICITY; DOSE RESPONSE; GALLSTONE; HEPATITIS; HIGH RISK POPULATION; HUMAN; IMPOTENCE; LIVER TOXICITY; MYOPATHY; OBESITY; PRIORITY JOURNAL; PRURITUS; REVIEW; SLEEP DISORDER;

EID: 0034792091     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118090-00003     Document Type: Review

References (185)

1. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up
2. The Helsinki Heart Study: An 8.5-year safety and mortality follow-up
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
8. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
9. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
10. Cholesterol reduction yields clinical benefit: A new look at old data
11. Clinical outcomes in statin treatment trials: A meta-analysis
12. HMG-CoA reductase inhibitor use in the aged: A review of clinical experience
13. Hypercholesterolemia in elderly persons: Resolving the treatment dilemma
14. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
15. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
16. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study
17. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients
18. Management of lipid disorders in the elderly
19. Long-term safety and efficacy profile of simvastatin
20. Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
21. Fluvastatin Long-Term Extension Trial (FLUENT): Summary of efficacy and safety
22. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
23. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings?
24. Preclinical evaluation of lovastatin
25. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin
26. Carcinogenicity of lipid-lowering drugs
27. Does lowering cholesterol cause cancer?
28. Carcinogenicity of lipid-lowering drugs
29. Carcinogenicity of lipid-lowering drugs
30. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells
31. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia
32. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
33. Serum cholesterol and cancer risk: An epidemiologic perspective
34. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial
35. Low serum cholesterol and the risk of cancer: An analysis of the published prospective studies
36. The Lipid Research Clinics Coronary Primary Prevention Trial: Results of 6 years of post-trial follow-up
37. Assessing possible hazards of reducing serum cholesterol
38. Clofibrate and niacin in coronary heart disease
39. Promoting effects of both dietary cholesterol and cholestyramine on pancreatic carcinogenesis initiated by N-nitrosobis(2-oxopropyl)amine in Syrian golden hamsters
40. Should there be a moratorium on the use of cholesterol lowering drugs?
41. An overview of trials of cholesterol lowering and risk of stroke
42. Incidence of cancer in men on a diet high in polyunsaturated fat
43. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
44. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer
45. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
46. Cerebrovascular diseases in a fixed population of Hiroshima and Nagasaki, with special reference to relationship between type and risk factors
47. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: A community-based mass screening in Okinawa, Japan
48. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program
49. Lipoproteins, cardiovascular disease, and death: The Framingham study
50. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study
51. Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women
52. Blood pressure, cholesterol, and stroke in eastern Asia
53. Serum cholestrol and haemorrhagic stroke in men. Korean Medical Insurance Corporation Study
54. Low serum cholestrol and intracerebral haemorrhagic stroke: Is the association confined to elderly men? Kaiser Permanente Medical Care Program
55. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
56. The paradox of high risk of stroke in populations with low risk of coronary heart disease
57. Low serum cholesterol and the risk of cerebral haemorrhage
58. Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
59. Reductase inhibitor monotherapy and stroke prevention
60. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
61. Pravastatin therapy and the risk of stroke
62. Stroke subtypes among Chinese living in Hong Kong: The Shatin Stroke Registry
63. Serum cholesterol concentration and death from suicide in men: Paris prospective study I
64. Association of low serum total cholesterol with major depression and suicide
65. Cholesterol, depression and suicide
66. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?
67. Low serum cholesterol concentration and serotonin metabolism in men
68. Low serum cholesterol and suicide
69. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys
70. HMG CoA reductase inhibitors and quality of life
71. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin
72. HMG-CoA reductase inhibitors for hypercholesterolemia
73. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia
74. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages
75. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance
76. Gemfibrozil-lovastatin-associated myalgia
77. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
78. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: A comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia
79. A review of clinical trials comparing HMG-CoA reductase inhibitors
80. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia
81. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
82. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study
83. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction
84. Gemfibrozil-induced impotence
85. Gemfibrozil-induced impotence
86. Gemfibrozil-induced impotence
87. HMG-CoA reductase inhibitor-induced impotence
88. Comment: HMG-CoA reductase inhibitor-induced impotence
89. Simvastatin impotence
90. Simvastatin seems unlikely to cause impotence
91. The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus
92. Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease?
93. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
94. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment
95. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia
96. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients
97. Clofibrate therapy and gallstone induction
98. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects
99. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment
100. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor
101. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia
102. Effects of lovastatin in humans on biliary lipid composition and secretion as a function of dosage and treatment interval
103. Effects of fluvastatin on human biliary lipids
104. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy
105. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
106. Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents
107. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
108. A comparison of simvastatin and atorvastatin up to maximum recommended doses in a large multicenter randomized clinical trial
109. Long term experience with simvastatin
110. Lovastatin-induced hepatitis
111. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin
112. Cholestatic jaundice associated with lovastatin (Mevacor) therapy
113. Acute cholestatic hepatitis during simvastatin administration
114. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin
115. Update of hepatotoxicity due to classes of drugs in common clinical use: Non-steroidal drugs, antiinflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents
116. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin
117. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin
118. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
119. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans
120. The prevalence of side effects with regular and sustained-release nicotinic acid
121. Acute hepatic failure associated with the use of low-dose sustained-release niacin
122. Hepatic toxicity of unmodified and time-release preparations of niacin
123. Pharmacokinetics of nicotinic acid-salicylic acid interaction
124. Antihyperlipidaemic agents: Drug interactions of clinical significance
125. Lovastatin-associated rhabdomyolysis
126. Clofibrate-induced muscular syndrome: Case report with ultrastructural findings and review of the literature
127. Gemfibrozil-induced myopathy
128. Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients
129. Efficacy and long-term adverse effect pattern of lovastatin
130. Potential risk of myopathy by HMG-CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers
131. Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
132. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors - Simvastatin and pravastatin
133. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
134. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
135. Evolution of the P450 gene superfamily: Animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation
136. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
137. Pathogenesis and management of lipoprotein disorders
138. Hepatitis and hematemesis complicating nicotinic acid use
139. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio
140. Simvastatin-induced acute pancreatitis: Two cases
141. A new case of simvastatin-induced acute pancreatitis
142. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine
143. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
144. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
145. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
146. New insights into the pharmacodynamic and pharmacokinetic properties of statins
147. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
148. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations
149. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
150. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase
151. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
152. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
153. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
154. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human P-450 and implications for metabolic drug interactions
155. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
156. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
157. Atorvastatin: Hydroxymethylglutaryl-coenzyme A reductase inhibitor
158. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
159. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
160. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
161. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model
162. HMG-CoA reductase inhibitors in organ transplantation
163. Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin
164. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
165. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
166. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
167. Rhabdomyolysis after taking atorvastatin with gemfibrozil
168. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
169. Drug interactions with fibric acids
170. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
171. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
172. Drug interactions of lipid-altering drugs
173. Lovastatin-induced myopathy in a hypothyroid patient
174. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias
175. Pharmacokinetics of fluvastatin and specific drug interactions
176. Fluvastatin with and without niacin for hypercholesterolemia
177. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
178. Adverse effects of hypolipidaemic drugs
179. Potential interaction between warfarin and fluvastatin
180. Potential warfarin-fluvastatin interaction
181. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
182. Lovastatin: Warfarin interaction
183. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
184. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
185. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion